Paclitaxel

About

Therapy type: Chemotherapy

Therapy strategy: Taxane-based chemotherapy

Mappings

NCI Thesaurus: Paclitaxel (coding:ncit:C1411)

RxNorm: paclitaxel (coding:rxcui:56946, coding:omop:1378382)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Paclitaxel
FDA (2) dMMR Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
FDA (2) MSI-H Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
EMA (1) FDA (2) dMMR Endometrial Carcinoma Carboplatin, Durvalumab, Paclitaxel
EMA (2) FDA (4) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
FDA (2) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Cisplatin, Paclitaxel, Pembrolizumab
FDA (2) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Cisplatin, Paclitaxel, Pembrolizumab
FDA (2) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
FDA (2) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (2) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Carboplatin, Paclitaxel, Pembrolizumab
FDA (2) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Carboplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (2) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (2) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (2) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
EMA (1) FDA (2) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab
EMA (2) FDA (8) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
EMA (1) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
EMA (1) FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel
EMA (2) HER2-positive Invasive Breast Carcinoma Paclitaxel, Trastuzumab
EMA (1) HER2-positive Invasive Breast Carcinoma Doxorubicin, Paclitaxel, Trastuzumab
EMA (2) ERBB2 amplification Invasive Breast Carcinoma Paclitaxel, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Doxorubicin, Paclitaxel, Trastuzumab
EMA (1) pMMR Endometrial Carcinoma Carboplatin, Durvalumab, Olaparib, Paclitaxel
EMA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Paclitaxel, Pembrolizumab
EMA (2) PD-L1 >= 1% Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
EMA (1) EGFR Somatic variants Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
EMA (1) v::ALK Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab
FDA (2) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab
FDA (2) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab
FDA (2) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab
FDA (2) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab
EMA (1) FDA (2) PD-L1 (CPS) >= 1 Ovarian Epithelial Tumor Paclitaxel, Pembrolizumab
EMA (1) FDA (2) PD-L1 (CPS) >= 1 Ovarian Epithelial Tumor Bevacizumab, Paclitaxel, Pembrolizumab
EMA (1) FDA (2) PD-L1 (CPS) >= 1 High-Grade Serous Fallopian Tube Cancer Paclitaxel, Pembrolizumab
EMA (1) FDA (2) PD-L1 (CPS) >= 1 High-Grade Serous Fallopian Tube Cancer Bevacizumab, Paclitaxel, Pembrolizumab
EMA (1) FDA (2) PD-L1 (CPS) >= 1 Peritoneal Serous Carcinoma Paclitaxel, Pembrolizumab
EMA (1) FDA (2) PD-L1 (CPS) >= 1 Peritoneal Serous Carcinoma Bevacizumab, Paclitaxel, Pembrolizumab